NYSEAMERICAN:MAIA MAIA Biotechnology (MAIA) Stock Price, News & Analysis $1.39 0.00 (0.00%) Closing price 04:10 PM EasternExtended Trading$1.38 -0.01 (-0.72%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock About MAIA Biotechnology Stock (NYSEAMERICAN:MAIA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MAIA Biotechnology alerts:Sign Up Key Stats Today's Range$1.36▼$1.4450-Day Range$1.20▼$2.4252-Week Range$0.87▼$3.19Volume410,852 shsAverage Volume692,444 shsMarket Capitalization$84.33 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview MAIA Biotechnology, Inc. is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications. The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods. In parallel, MAIA Biotechnology is advancing therapeutic constructs that couple monoclonal antibodies to therapeutic radioisotopes for selective tumor cell eradication. These efforts are supported by in‐house radiochemistry capabilities and collaborative research partnerships with academic institutions. Headquartered in the United States, MAIA Biotechnology serves both domestic and international research markets and is preparing key assets for regulatory submission and first‐in‐human trials. The management team comprises industry veterans in radiopharmaceutical development and antibody engineering, and the company continues to expand its platform technology to address unmet needs in cancer diagnosis and treatment.AI Generated. May Contain Errors. Read More MAIA Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreMAIA MarketRank™: MAIA Biotechnology scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for MAIA Biotechnology. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of MAIA Biotechnology is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MAIA Biotechnology is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMAIA Biotechnology has a P/B Ratio of 23.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about MAIA Biotechnology's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.83% of the float of MAIA Biotechnology has been sold short.Short Interest Ratio / Days to CoverMAIA Biotechnology has a short interest ratio ("days to cover") of 4.06.Change versus previous monthShort interest in MAIA Biotechnology has recently increased by 23.02%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMAIA Biotechnology does not currently pay a dividend.Dividend GrowthMAIA Biotechnology does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.65 News SentimentMAIA Biotechnology has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for MAIA Biotechnology this week, compared to 2 articles on an average week.Search Interest23 people have searched for MAIA on MarketBeat in the last 30 days. This is an increase of 1,050% compared to the previous 30 days.MarketBeat Follows3 people have added MAIA Biotechnology to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MAIA Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders19.81% of the stock of MAIA Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions5.65% of the stock of MAIA Biotechnology is held by institutions.Read more about MAIA Biotechnology's insider trading history. Receive MAIA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MAIA Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MAIA Stock News HeadlinesMAIA Biotechnology (MAIA) to Release Earnings on FridayMay 1, 2026 | americanbankingnews.comMAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung CancerApril 16, 2026 | markets.businessinsider.com$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…May 5 at 1:00 AM | Paradigm Press (Ad)MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer TherapyApril 8, 2026 | globenewswire.comMAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung CancerMarch 31, 2026 | globenewswire.comMAIA Biotechnology (MAIA) price target increased by 18.16% to 12.38March 27, 2026 | msn.comDiamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)March 27, 2026 | globenewswire.comDiamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)March 5, 2026 | globenewswire.comSee More Headlines MAIA Stock Analysis - Frequently Asked Questions How have MAIA shares performed this year? MAIA Biotechnology's stock was trading at $1.53 at the beginning of the year. Since then, MAIA stock has decreased by 9.2% and is now trading at $1.39. How were MAIA Biotechnology's earnings last quarter? MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) released its quarterly earnings data on Monday, March, 23rd. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.05. How do I buy shares of MAIA Biotechnology? Shares of MAIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MAIA Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that MAIA Biotechnology investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Jabil (JBL), Adobe (ADBE) and AppLovin (APP). Company Calendar Last Earnings3/23/2026Today5/05/2026Next Earnings (Estimated)5/08/2026AGM 20265/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 MAIA's financial health is in the Yellow zone, according to TradeSmith. MAIA has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:MAIA CIK1878313 Webwww.MAIABiotech.com Phone312-416-8592FaxN/AEmployees9Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$22.40 million Net MarginsN/A Pretax MarginN/A Return on Equity-797.18% Return on Assets-201.77% Debt Debt-to-Equity RatioN/A Current Ratio1.66 Quick Ratio1.66 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.06 per share Price / Book23.17Miscellaneous Outstanding Shares60,670,000Free Float48,652,000Market Cap$84.33 million OptionableNot Optionable Beta0.21 The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NYSEAMERICAN:MAIA) was last updated on 5/5/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSell 99% of Your Stocks, Do THIS Instead…Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...The Oxford Club | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredElon Unveils AI Passive Income Stream for Millions of AmericansDuring Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MAIA Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MAIA Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
